CardioNet, Inc. (NASDAQ: BEAT) announced today that the 300,000th 
      patient has been monitored with the Company’s Mobile Cardiac Outpatient 
      Telemetry (MCOT™) service. MCOT is the first system to provide real-time 
      wireless ECG monitoring and 24/7/365 analysis and response.
    
“The ability to immediately detect a cardiac arrhythmia and then closely 
      monitor the patient for repeat occurrences provides numerous treatment 
      advantages, not the least of which is giving the cardiologist an 
      opportunity to address the condition before it causes a more severe, 
      potentially irreparable outcome”
    
      Randy Thurman, CardioNet Chairman, President and CEO, commented, “With 
      300,000 patients having now benefited from our MCOT service, it is 
      evident that an increasing number of physicians view real-time, 24/7 
      monitoring of cardiac arrhythmias as crucial to identifying and 
      preventing life-threatening cardiac-related events such as stroke. The 
      continued availability and adoption of MCOT also brings value to the 
      entire healthcare continuum as it enables physicians to manage 
      arrhythmias before they manifest into more severe conditions that demand 
      significantly greater costs and resources to treat.”
    
    
      MCOT offers several advantages to physicians, payors, and patients, 
      including: real-time, continuous ECG data analysis; customizable concise 
      reporting to enhance diagnosis and treatment decisions; increased 
      patient compliance through technology and reduced interaction; 
      reflection of real-life cardiac activity; detection of arrhythmias where 
      symptoms are not experienced; minimization of data artifacts or “noise”; 
      two-way wireless capabilities for transmission; ability to associate 
      symptoms and activity with ECG event; remote programming and data 
      retrieval; and the ability to tailor the system to physicians’ needs. 
      Due to these advantages, CardioNet’s MCOT continues to increase its 
      significant leadership position in the mobile cardiac telemetry market.
    
    
      Dr. Paul Schweitzer, Director of Cardiac Arrhythmia Service at Beth 
      Israel Medical Center and Asst. Chief of Cardiology at Albert Einstein 
      College of Medicine in New York City treated the 300,000th MCOT patient.
    
    
      “The ability to immediately detect a cardiac arrhythmia and then closely 
      monitor the patient for repeat occurrences provides numerous treatment 
      advantages, not the least of which is giving the cardiologist an 
      opportunity to address the condition before it causes a more severe, 
      potentially irreparable outcome,” said Dr. Schweitzer. “Through its 
      beat-by-beat wireless monitoring, MCOT provides assurance that these 
      sometimes difficult to detect irregularities will be diagnosed in a 
      manner that allows the physician to understand the root cause and 
      prescribe a course of action for the patient’s individual needs.”